BRD4 and melanoma: To further elucidate the specific protein that mediates BET inhibitor-induced sensitization of melanoma cells to sunitinib, we overlapped the downregulated differentially expressed genes after BET inhibitor treatment and after BRD4 silencing (Fig. 5c).